Characteristics of Patients With Recessive Dystrophic Epidermolysis Bullosa
Trial ID or NCT#
NCT01019148
Status
RECRUITING
Purpose
Recessive dystrophic epidermolysis bullosa (RDEB) is a disease caused by genetic mutations in the gene for type VII collagen. Patients with RDEB develop large, severely painful blisters and open wounds from minor trauma to their skin. We are screening subjects with RDEB to evaluate characteristics of the subjects and their cells in order to develop new strategies of therapy and determine whether subjects could be candidates for treatment studies.
Official Title
Characteristics of Patients With Recessive Dystrophic Epidermolysis Bullosa
Eligibility Criteria
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Inclusion Criteria:
- - Clinical diagnosis of RDEB by local dermatologist - 7 years of age or older
Exclusion Criteria:
- -Medical instability limiting ability to travel to Stanford University Medical Center
Investigator(s)
Jean Y. Tang MD PhD
General dermatologist,
Dermatologic oncologist,
Cutaneous oncology specialist
Professor of Dermatology
Marius Wernig
Anthony Oro, MD, PhD
Hair loss specialist,
Dermatologic oncologist,
Cutaneous oncology specialist,
Skin stem cell specialist
Eugene and Gloria Bauer Professor
M. Peter Marinkovich, MD
Dermatologist,
Blistering disease specialist,
Psoriasis specialist
Associate Professor of Dermatology
Paul A. Khavari, MD, PhD
Dermatologist,
Cutaneous oncology specialist,
Medical oncologist
Carl J. Herzog Professor of Dermatology in the School of Medicine
Contact us to find out if this trial is right for you.
Contact
Irene Bailey-Healy
650-721-7149
View on ClinicalTrials.gov
